Literature DB >> 19804765

Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.

Sung Tae Kim1, Hyo Jin Son, Ji Hyun Choi, In Jung Ji, Onyou Hwang.   

Abstract

Parkinson's disease (PD) is caused by selective degeneration of the nigral dopaminergic (DArgic) neurons and is accompanied by motor dysfunctions such as tremor, akinesia, and rigidity. Changes in the degree of motor deficit can be utilized as a noninvasive way of assessing alterations in the number of DArgic neurons and/or the amount of DA in animal models of PD, such as mice systemically administrated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In this study, in order to develop sensitive methods to detect DA-associated motor deficits, we designed a new test called vertical grid test and modified the existing horizontal grid test. After acute MPTP treatment, decreases in the levels of striatal DA (17.4% of control), dihydroxyphenylacetic acid (33.3%), and homovanillic acid (40.5%) were observed. On the modified horizontal grid test, the MPTP-administered mice exhibited average forelimb step distance that was lower than control (82.58%) and correlated with the striatal DA levels. On the vertical grid test, the MPTP-treated mice took dramatically longer total time to climb down (220.94%) and time to make the turn (339.29%) compared to control, and this correlated well with the degree of striatal DA depletion. In comparison, the gait test produced only a small, albeit statistically significant, reduction in the mean stride length (94.55% of control). These results show that the vertical grid test can provide a sensitive measure of motor deficit in mice following administration of MPTP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804765     DOI: 10.1016/j.brainres.2009.09.103

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  31 in total

1.  Natural toxins implicated in the development of Parkinson's disease.

Authors:  Mohamed Salama; Oscar Arias-Carrión
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

2.  A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.

Authors:  Hyo Jin Son; Ji Ae Lee; Nari Shin; Ji Hyun Choi; Jai Woong Seo; Dae Yoon Chi; Cheol Soon Lee; Eun-Mee Kim; Han Choe; Onyou Hwang
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson's Disease Model in Mice.

Authors:  Sugumar Mani; Sathiya Sekar; Rajamani Barathidasan; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Murugan Sevanan; Saravana Babu Chidambaram; Musthafa Mohamed Essa; Gilles J Guillemin; Meena Kishore Sakharkar
Journal:  Neurotox Res       Date:  2018-02-09       Impact factor: 3.911

4.  Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator.

Authors:  Ji Won Choi; Su Jeong Shin; Hyeon Ji Kim; Jong-Hyun Park; Hyeon Jeong Kim; Elijah Hwejin Lee; Ae Nim Pae; Yong Sun Bahn; Ki Duk Park
Journal:  ACS Med Chem Lett       Date:  2019-06-03       Impact factor: 4.345

Review 5.  Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.

Authors:  Edward A Lock; Jing Zhang; Harvey Checkoway
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-07       Impact factor: 4.219

6.  Parkinson's disease: is it a toxic syndrome?

Authors:  Seham A Gad Elhak; Abdel Aziz A Ghanem; Hassan Abdelghaffar; Sahar El Dakroury; Mohamed M Salama
Journal:  Neurol Res Int       Date:  2010-09-05

7.  A Novel Compound ITC-3 Activates the Nrf2 Signaling and Provides Neuroprotection in Parkinson's Disease Models.

Authors:  Ji Ae Lee; Hyo Jin Son; Ki Duk Park; Se Hee Han; Nari Shin; Ji Hyun Kim; Hye Ri Kim; Dong Jin Kim; Onyou Hwang
Journal:  Neurotox Res       Date:  2015-08-02       Impact factor: 3.911

8.  Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.

Authors:  Nian Xiong; Jing Xiong; Ghanshyam Khare; Chunnuan Chen; Jinsha Huang; Ying Zhao; Zhentao Zhang; Xian Qiao; Yuan Feng; Harrish Reesaul; Yongxue Zhang; Shenggang Sun; Zhicheng Lin; Tao Wang
Journal:  PLoS One       Date:  2011-06-03       Impact factor: 3.240

9.  Amelioration of behavioral abnormalities in BH(4)-deficient mice by dietary supplementation of tyrosine.

Authors:  Sang Su Kwak; Mikyoung Jeong; Ji Hye Choi; Daesoo Kim; Hyesun Min; Yoosik Yoon; Onyou Hwang; Gary G Meadows; Cheol O Joe
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.

Authors:  Xiao Hong Wang; Gang Lu; Xiang Hu; Kam Sze Tsang; Wing Hang Kwong; Feng Xia Wu; Hai Wei Meng; Shu Jiang; Shu Wei Liu; Ho Keung Ng; Wai Sang Poon
Journal:  BMC Neurosci       Date:  2012-11-14       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.